Executive Summary
Today's filings reveal a bifurcated market: capital-intensive transformation stories (AXISCADES, NRB Bearings, Kabra Drugs) are driving high-conviction positive signals, while governance and insolvency risks (Radhagobind Commercial, SIS Limited) remain elevated. The standout is AXISCADES' ₹2,256 Cr divestment completion, fully funding a ₹9,000 Cr revenue target by FY30 and positioning it as a pure-play defence/ESAI platform—a structural re-rating catalyst.
NRB Bearings' sharp reduction in promoter pledge from 31.64% to 11.42% signals improved financial health, supported by 11% revenue growth and 19.5% EBITDA margins. Jio Platforms' leap into global top-20 patent filers reinforces India's deep-tech narrative, though the sector remains capital-intensive. On the negative side, Radhagobind Commercial's ongoing CIRP and SIS Limited's profit inadequacy highlight persistent stress in select corporates. Overall, the theme of 'asset-light to asset-heavy pivot' dominates, with significant capital allocation shifts toward manufacturing, defence, and pharma.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Filing types in this digest: Corporate action · Corporate governance · Company update · Insider trading · Insolvency
Tracking the trend? Catch up on the prior India Stock Market Daily Regulatory Digest digest from June 13, 2026.
Investment Signals (10)
- AXISCADES Technologies ↓ (BULLISH)▲
Completed Phase 2 divestment of aerospace engineering services for total ~₹2,256 Cr ($237 Mn), fully funding Power 930 plan targeting ₹9,000 Cr revenue and ₹960 Cr PAT by FY30. ~80% of FY27 revenue from Defence/ESAI, with 3 acquisitions closing in FY27.
- NRB Bearings (BULLISH)▲
Promoter pledge reduced from 31.64% to 11.42% (19.6 million shares released) via block deal with institutional investors. FY26 revenue grew 11% YoY with 19.5% EBITDA margin. Industrial segment target of 25% by 2031 (currently 12-14%) provides long-term growth runway.
- Jio Platforms (Reliance Industries) (BULLISH)▲
Entered global top-20 WIPO PCT rankings (climbed 320 places), only Indian tech innovator in top 20. Cumulative 6,817 patents filed, 1,009 granted. Deep-tech focus on 5G/6G, AI, satellite comms—positions for next-gen telecom monetization.
- Kabra Drugs ↓ (BULLISH)▲
Received ₹200 Cr Letter of Intent from Chhattisgarh government for pharma manufacturing park, expected 250 jobs. Aligns with state incentives but subject to definitive agreements—early-stage catalyst with execution risk.
- SIS Limited ↓ (MIXED)▲
Profit inadequacy for FY2025-26 flagged in AGM notice, yet MD remuneration revised upward by ~6.7% (₹2.40 Cr to ₹2.56 Cr). Contradictory signals—management confidence vs. weak earnings—warrant caution.
- Mid India Industries ↓ (NEUTRAL)▲
Promoter Pradeep Ganediwal acquired 8,56,126 shares via transmission (not market purchase). No insider buying conviction—purely administrative.
- Radhagobind Commercial ↓ (BEARISH)▲
9th CoC meeting scheduled June 15 to discuss CIRP extension and resolution plan due diligence. Ongoing insolvency with no resolution in sight—negative for equity holders.
- Sun Pharmaceutical Industries ↓ (NEUTRAL)▲
Independent Director Gautam Doshi arrested—company states no impact on operations. While isolated, reputational risk for board governance remains.
- Lippi Systems ↓ (NEUTRAL)▲
EGM approved increase in authorized capital and preferential issue of convertible warrants—potential equity dilution ahead.
- Deepak Spinners ↓ (NEUTRAL)▲
Appointed new Senior VP with 38 years experience—operational stability signal but no financial impact.
Risk Flags (8)
- SIS Limited/Profit Inadequacy↓ [HIGH RISK]▼
FY2025-26 profits inadequate, yet board proposes higher MD remuneration (₹2.56 Cr vs ₹2.40 Cr). Raises governance questions on pay-for-performance alignment.
- Radhagobind Commercial/Insolvency↓ [HIGH RISK]▼
9th CoC meeting on June 15 with agenda including CIRP extension—no resolution plan approved yet. Equity value likely zero in liquidation scenario.
- Sun Pharma/Board Governance↓ [MEDIUM RISK]▼
Independent Director arrest (Gautam Doshi) creates reputational overhang. While company distances itself, SEBI may scrutinize board processes.
- AXISCADES/Execution Risk↓ [MEDIUM RISK]▼
₹2,256 Cr divestment proceeds contingent on milestones—Tranche 1 in Q3 FY27, Tranche 2 in H1 FY28, residual stake in FY29. Any delay impacts Power 930 funding.
- Kabra Drugs/Project Risk↓ [MEDIUM RISK]▼
₹200 Cr LOI is non-binding—subject to definitive agreements and approvals. No timeline provided; execution failure would reverse positive sentiment.
- NRB Bearings/Industrial Segment Gap [MEDIUM RISK]▼
Industrial segment at 12-14% of revenue vs 25% target by 2031—significant gap requiring aggressive M&A or organic growth. International sales at 20-25% exposed to FX and tariff risks.
- Cranes Software/Delayed Results↓ [MEDIUM RISK]▼
Adjourned board meeting on June 15 for FY26 results after prior delay (May 30). Repeated delays may indicate accounting or operational issues.
- Lippi Systems/Dilution Risk↓ [LOW RISK]▼
Preferential warrant issuance could dilute existing shareholders if converted. No details on conversion price or timeline provided.
Opportunities (7)
- AXISCADES/Structural Re-rating↓ (OPPORTUNITY)◆
Post-divestment, company is a pure-play defence, space, electronics, semiconductors, and AI platform. Power 930 plan implies ~3x revenue growth by FY30. With ₹2,256 Cr cash, M&A pipeline (3 deals in FY27) could accelerate.
- NRB Bearings/Deleveraging Catalyst (OPPORTUNITY)◆
Promoter pledge reduction from 31.64% to 11.42% removes overhang. Strong FY26 (11% revenue growth, 19.5% EBITDA margin) combined with institutional interest (Arohi, PGIM, Alchemy) suggests re-rating potential.
- Jio Platforms/Patent Monetization (OPPORTUNITY)◆
Top-20 global patent filer status could lead to licensing revenue or strategic partnerships in 5G/6G and AI. With 6,817 patents, Jio is building a defensible moat in telecom tech.
- Kabra Drugs/Pharma Park Incentives↓ (OPPORTUNITY)◆
Chhattisgarh's Nava Raipur Pharma Park offers state subsidies—if definitive agreements close, ₹200 Cr project could boost capacity and margins. Early-stage but high-upside for a small-cap.
- Belrise Industries/Compliance Strengthening↓ (OPPORTUNITY)◆
Appointment of experienced CS & Compliance Officer (20 years) and clear KMP designation under SEBI Reg 30 signals improved governance—positive for institutional investor confidence.
- Deepak Spinners/Operational Stability↓ (OPPORTUNITY)◆
New unit head with 38 years experience at Guna Works could drive efficiency improvements. Textile sector cyclical recovery may benefit from experienced leadership.
- TCFC Finance/AGM Catalyst↓ (OPPORTUNITY)◆
AGM on July 30 with e-voting from July 27-29. While procedural, any special resolutions or dividend announcements could emerge—watch for shareholder returns.
Sector Themes (5)
- Defence/Manufacturing Pivot◆
AXISCADES and NRB Bearings both highlight shift from services to manufacturing/defence. AXISCADES targets 80% revenue from Defence/ESAI by FY27; NRB targets 25% industrial by 2031. Capital allocation is flowing toward asset-heavy, high-IP businesses. [IMPLICATION: Favor companies with defence/industrial exposure over pure services.]
- Insolvency & Governance Stress◆
Radhagobind Commercial (CIRP) and SIS Limited (profit inadequacy) show that corporate distress persists despite market highs. Sun Pharma's director arrest adds governance scrutiny. Investors should screen for high promoter pledge and weak earnings coverage. [IMPLICATION: Avoid companies with unresolved insolvency or repeated profit inadequacy.]
- Patent & IP Leadership as Moat◆
Jio Platforms' top-20 global patent ranking underscores that Indian companies are investing in deep-tech IP. This creates long-term competitive advantages in 5G/6G and AI, potentially leading to licensing revenue. [IMPLICATION: Monitor patent filing trends as leading indicator of tech moat.]
- Capital Allocation Divergence◆
While AXISCADES and NRB Bearings are deleveraging and reinvesting in growth, SIS Limited is raising MD pay despite profit inadequacy. The divergence highlights the importance of capital allocation discipline in stock selection. [IMPLICATION: Favor companies with transparent capital allocation and aligned incentives.]
- Pharma Manufacturing Capex Cycle◆
Kabra Drugs' ₹200 Cr LOI signals revival in pharma manufacturing investments, supported by state-level incentives. This aligns with the broader 'China+1' and PLI-driven capex cycle in Indian pharma. [IMPLICATION: Watch for more such LOIs and project announcements in pharma parks.]
Watch List (8)
-
Watch for Q3 FY27 cash inflow from Tranche 1 of Phase 2 divestment and announcement of 3 planned acquisitions. Key catalyst for Power 930 plan execution.
-
9th CoC meeting on June 15—outcome on CIRP extension and resolution plan due diligence critical. Any positive development could trigger short-term rally, but equity recovery unlikely.
-
AGM on July 6—watch for shareholder voting on executive remuneration and any guidance on profit recovery. Profit inadequacy resolution path is key.
- NRB Bearings👁
Monitor industrial segment growth trajectory and any further pledge reduction. Block deal institutional investors' holding period will signal conviction.
-
Definitive agreement signing and project timeline for ₹200 Cr pharma park. Any delay beyond 3 months would be negative.
-
Adjourned board meeting on June 15 for FY26 results—watch for any qualified audit opinion or material adjustments after prior delay.
-
SEBI or regulatory follow-up on independent director arrest—any board-level action or resignation would be material.
-
Conversion of preferential warrants—monitor for dilution impact and use of proceeds from capital increase.
Filing Analyses
(16)
13-06-2026
SIS Limited has published its Integrated Annual Report for FY2025-26 and convened its 42nd Annual General Meeting (AGM) to be held via video conferencing on July 6, 2026. The AGM agenda includes adoption of audited financial statements, re-appointment of directors, and special resolutions to appoint Mrs. Rita Kishore Sinha as Executive Chairperson (effective May 1, 2026) and to revise remuneration for the Managing Director and Whole-Time Director. Notably, the company reported inadequacy of profits for FY2025-26, which is a negative signal, while the remuneration revisions reflect continued investment in leadership.
- · The 42nd AGM will be held on July 6, 2026 at 12:00 Noon IST via Video Conferencing/Other Audio Visual Means.
- · Special resolutions include appointment of Mrs. Rita Kishore Sinha as Executive Chairperson for 5 years from May 1, 2026, with minimum remuneration provisions due to inadequacy of profits.
- · Revision in remuneration for Managing Director Mr. Rituraj Kishore Sinha from ₹2,40,00,000 to ₹2,56,00,000 per annum effective June 1, 2026.
- · Revision in remuneration for Whole-Time Director Mr. Arvind Kumar Prasad from ₹1,00,00,000 to ₹1,07,99,978 per annum effective June 1, 2026.
- · Proposed aggregate remuneration of up to ₹1,60,00,000 for Independent Directors for FY ended March 31, 2026, in addition to sitting fees.
- · The company reported inadequacy of profits for FY2025-26, which is cited as the reason for seeking approval to pay minimum remuneration under Schedule V of the Companies Act.
14-06-2026
NaBFID (National Bank for Financing Infrastructure and Development) has informed stock exchanges that the record date for annual interest payment on its 7.43% Non-Convertible Debentures (ISIN INE0KUG08035) is June 20, 2026, with interest payment due on July 4, 2026. The annual interest amount per debenture is ₹7,430.
- · Record date for interest payment: June 20, 2026
- · Interest payment date: July 4, 2026
- · Debentures listed on BSE (scrip code 975800) and NSE
- · Filing made under Regulation 60(2) of SEBI (LODR) Regulations, 2015
14-06-2026
Cranes Software International Ltd. has informed BSE that its adjourned Board Meeting is now scheduled for June 15, 2026, to consider and approve the standalone and consolidated audited financial results for the financial year ended March 31, 2026. This follows a prior delay in approval, as intimated on May 30, 2026. The meeting is an adjournment of the previous Board and Audit Committee meetings.
- · The company had previously intimated a delay in approval of audited financial results for FY ended March 31, 2026, via a letter dated May 30, 2026.
- · The adjourned Board Meeting is scheduled for Monday, June 15, 2026.
- · The meeting will consider both standalone and consolidated audited financial results for the financial year ended March 31, 2026.
- · The meeting is an adjournment of the previous Board Meeting and the Audit Committee Meeting.
14-06-2026
Sun Pharmaceutical Industries Limited has informed the exchanges of the arrest of its Independent Director, Mr. Gautam Doshi, stating that the matter is not connected with the Company and that no impact is envisaged on the Company or its board processes. The Company will continue to monitor the situation and take appropriate steps based on further developments.
- · The arrest was reported under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- · The registered office of Sun Pharma is in Vadodara, Gujarat.
- · The corporate office is located in Goregaon (East), Mumbai.
14-06-2026
Lippi Systems Ltd. held its 01/2026-27 Extra-Ordinary General Meeting on June 14, 2026, to seek shareholder approval for two special resolutions: an increase in authorized share capital with consequent alteration of the Memorandum of Association, and the issuance of convertible equity warrants on a preferential basis for cash consideration. The meeting was conducted via remote e-voting and physical poll, with no questions or queries raised by members. The voting results and scrutinizer's report are to be announced within two working days.
- · The EGM was held on Sunday, June 14, 2026, from 11:30 AM to 11:50 AM IST at the registered office in Ahmedabad.
- · Remote e-voting was open from June 11, 2026 (9:00 AM IST) to June 13, 2026 (5:00 PM IST).
- · No questions or queries were raised by shareholders during the meeting.
- · The scrutinizer for the e-voting and physical poll process is Ms. Rupal Patel, Practicing Company Secretary.
- · Combined voting results will be announced within 2 working days of the EGM.
14-06-2026
TCFC Finance Ltd published newspaper advertisements on June 14, 2026, regarding its 35th Annual General Meeting (AGM) scheduled for July 30, 2026, with a record date of June 9, 2026. The notice also includes a public notice for passport record clarification and a divorce deed name variation, along with details of e-voting and remote e-voting procedures. The filing is largely procedural and does not disclose any financial results or material business updates.
- · The AGM is scheduled for July 30, 2026, with a record date of June 9, 2026.
- · Remote e-voting will commence at 9:00 AM on July 27, 2026, and end at 5:00 PM on July 29, 2026.
- · The public notice includes a divorce deed name variation and passport record clarification for Haresh Ambavi Vaviya.
- · Shareholders can raise objections within 60 days of the notice.
- · The filing includes details of immovable property (land) with area 29.87 sq. meters and 107.90 sq. meters mentioned in the notice.
14-06-2026
Jio Platforms, a subsidiary of Reliance Industries, has surged into the global top 20 in the latest WIPO Patent Co-operation Treaty (PCT) rankings for 2025, climbing 320 places. This makes it the only Indian technology innovator in the top 20, alongside global leaders like Huawei, Samsung, and Qualcomm. The achievement highlights Jio's deep-tech focus on 5G, 6G, AI, and other next-generation technologies, though global PCT filings grew by less than 1% in the same period.
- · Jio Platforms has filed 6,817 patents cumulatively as of March 31, 2026, with 2,393 in India and 4,424 in foreign jurisdictions.
- · A total of 1,009 patents have been granted globally, comprising 538 grants in India and 471 in international markets.
- · Jio is developing sunrise technologies including 5G/6G Radio, 5G/6G Core, satellite communications, and Agentic AI – JioBrain.
- · Global PCT filings grew by less than 1% in 2025, making Jio's 320-rank jump even more notable.
14-06-2026
Mid India Industries Limited disclosed that promoter Mr. Pradeep Ganediwal acquired 8,56,126 equity shares through transmission on June 11, 2026, following the death of Late Shri Ranchhod Prasad Ganediwal, also a promoter. The shares were previously held by the deceased and have been transmitted to Mr. Pradeep Ganediwal. This is a routine disclosure under SEBI insider trading regulations and does not involve any market purchase or sale.
- · Transmission date: June 11, 2026
- · Filing date: June 14, 2026
- · BSE Scrip Code: 500277, ISIN: INE401C01018
- · Regulation 7(2) read with Regulation 6(2) of SEBI (Prohibition of Insider Trading) Regulations, 2015
14-06-2026
Kabra Drugs Ltd has received a Letter of Intent from the Government of Chhattisgarh for a ₹200 Crore pharmaceutical manufacturing project at Nava Raipur Pharma Park. The project is expected to generate approximately 250 direct and indirect employment opportunities and aligns with the company's long-term expansion strategy. However, the investment remains subject to definitive agreements and necessary approvals, and no timeline for completion has been provided.
- · The LOI was received on June 12, 2026.
- · The project is located at Nava Raipur Pharma Park, Chhattisgarh.
- · The company expects to benefit from state government policies and incentives, subject to sanction orders.
- · The investment is subject to execution of definitive agreements and receipt of necessary approvals.
- · Kabra Drugs is a research-driven company focused on specialty formulations, injectables, and APIs, with WHO-GMP aligned systems.
14-06-2026
SIS Limited has informed stock exchanges about the publication of newspaper advertisements regarding the dispatch of the Notice of the 42nd Annual General Meeting and the Annual Report for FY 2025-26, along with the availability of remote e-voting. The advertisements were published in English and Hindi newspapers on June 14, 2026. No financial results or performance metrics are disclosed in this filing.
- · The company's CIN is L75230BR1985PLC002083.
- · Registered office is at Annapoorna Bhawan, Patliputra Telephone Exchange Road, Kurji, Patna 800 010, Bihar.
- · Correspondence address is #106, 1st Floor, Ramanashree Arcade, 18 MG Road, Bangalore-560 001, Karnataka.
- · The filing is a procedural disclosure under Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015.
14-06-2026
AXISCADES Technologies Limited announced the conclusion of its Phase 2 Divestment of Aerospace Engineering Services, completing a combined two-phase Engineering Services Divestment Programme valued at ~₹2,256 Cr (~US$237 Mn, including contingent payments). The proceeds fully fund the Power 930 plan through FY2030, which targets ₹9,000 Cr revenue and ₹960 Cr PAT by FY30. The company is now structurally a manufacturing, defence, space, electronics, semiconductors and AI platform, with ~80% of FY27 revenue targeted from Defence and ESAI organic conversion and ~20% from three planned acquisitions scheduled to close in FY27.
- · Phase 2 signed on 12 June 2026, with cash inflows scheduled for Q3 FY27 (Tranche 1) and H1 FY28 (Tranche 2), and residual stake transfer in FY29.
- · Combined programme value of ~$237 Mn / ~₹2,256 Cr includes minimum ~$177 Mn (~₹1,685 Cr) plus contingent ~$60 Mn (~₹571 Cr).
- · The company targets ~80% of FY27 revenue from Defence and ESAI organic conversion and ~20% from 3 planned acquisitions, all scheduled to close in FY27.
- · Investment allocation: Defence Solutions ₹600 Cr (₹300 Cr DAC + ₹300 Cr MAC), Aerospace Manufacturing ₹600 Cr (₹150 Cr DAC + ₹450 Cr acquisitions), Space Systems ₹300 Cr (₹120 Cr facilities & training + ₹180 Cr JVs), XiDA Inc ₹300 Cr (₹90 Cr facilities + ₹210 Cr acquisitions).
- · The XiDA Inc vehicle is designed for US ESAI acquisitions with a mirroring architecture to replicate capabilities at DAC in India.
- · Space Systems division will bypass organic stages 1-3 through strategic partnerships and JVs, moving directly to stages 4 and 5.
14-06-2026
NRB Bearings announced a major reduction in promoter pledge from 31.64% to 11.42%, with MD Harshbeena Zaveri releasing 19.6 million shares from pledge. The company reported strong FY26 results with 11% revenue growth and a strong 19.5% EBITDA margin. While core auto and industrial segments are expanding, the industrial segment currently contributes only 12-14% of revenue, well below the 25% target set for 2031.
- · Promoter-level debt was reduced through a block deal involving institutional investors Arohi Capital, PGIM, Alchemy, and Arcadian.
- · NRB targets to grow industrial segment to 25% of total revenue by 2031 (currently 12-14%).
- · International sales contribute 20-25% of revenue, supported by a 'Make in USA' strategy.
- · Over 30% of management is under age 35, and the company is certified as a 'Great Place to Work'.
14-06-2026
Radhagobind Commercial Limited has informed stock exchanges that the 9th meeting of the Committee of Creditors (CoC) is scheduled for June 15, 2026, to discuss the progress of the Corporate Insolvency Resolution Process (CIRP), including an NCLT order reserved for extension, appointment of a legal consultant for verification and due diligence of resolution plans, and CIRP costs and interim finance. The company is under insolvency proceedings with an Interim Resolution Professional appointed by the NCLT, Kolkata Bench.
- · The 9th CoC meeting will be held on June 15, 2026 at 5:00 PM at Baithussalam, Balankinar, Kattampally Road, Kannur, Kerala, and via video conferencing.
- · Agenda includes discussion on NCLT order reserved for extension of CIRP, appointment of a legal consultant for verification and due diligence of resolution plans, and CIRP costs and interim finance from financial creditors.
- · The company's CIN is L51909WB1981PLC033680 and scrip codes are 030070 (BSE) and 539673 (CSE).
14-06-2026
Deepak Spinners Ltd. announced the appointment of Shri Nandkishore Khandelwal as Senior Vice President and Unit Head of its Guna Works, effective June 15, 2026. The appointment was approved by the Board via circular resolution on June 13, 2026, based on the recommendation of the Nomination and Remuneration Committee. Shri Khandelwal brings 38 years of textile industry experience to the role.
- · The appointment is effective from June 15, 2026.
- · Shri Khandelwal holds a BSc degree from Rajasthan University, Jaipur.
- · His previous employers include Eastern Spinning Mills, Kolkata; Gujarat Spinning Limited, Rajkot; Rajasthan Textile Mills; and Sutlej Textiles & Industries Ltd.
- · Terms of appointment are in accordance with the company's Nomination and Remuneration policy.
14-06-2026
Belrise Industries Limited has appointed Mr. Siddhesh Mandke as Company Secretary & Compliance Officer (KMP) and Head of Legal, effective June 14, 2026. Mr. Mandke brings 20 years of experience in corporate laws, legal affairs, and compliance management, having previously worked at Vascon Engineers Limited, Kirloskar Corrocoat Pvt Limited, Kirloskar Brothers Limited, and Finolex Cables Limited.
- · Mr. Mandke is an Associate Member (A20101) of the ICSI, New Delhi, and holds M.Com, DBM, MMS (Finance), and LLB degrees from Pune University.
- · The appointment was made pursuant to the recommendation of the Nomination and Remuneration Committee and approved by the Board of Directors.
- · The appointment is under Section 203 of the Companies Act, 2013 and Regulation 6(1) of the SEBI Listing Regulations.
14-06-2026
Belrise Industries Limited has informed the stock exchanges of the authorized Key Managerial Personnel (KMPs) responsible for determining materiality of events and making disclosures under Regulation 30 of SEBI Listing Regulations. The designated KMPs are Chief Financial Officer Mr. Rahul Ganu and Company Secretary & Compliance Officer Mr. Siddhesh Mandke.
- · Filing made under Regulation 30(5) of SEBI Listing Regulations, 2015.
- · The authorized KMPs are: Mr. Rahul Ganu (CFO) and Mr. Siddhesh Mandke (CS & Compliance Officer).
- · Contact details provided: email and phone number for both KMPs.
- · Submission available on company website under 'Investor Relations'.
- · No financial figures or performance data are contained in this filing.
Get daily alerts with 10 investment signals, 8 risk alerts, 7 opportunities and full AI analysis of all 16 filings
₹500/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: India Stock Market Daily Regulatory Digest
🇮🇳 More from India
View all →June 15, 2026
India Upcoming Corporate Actions BSE NSE — June 15, 2026
India Upcoming Corporate Actions BSE NSE
June 15, 2026
India AGM EGM Shareholder Meeting Schedule — June 15, 2026
India AGM EGM Shareholder Meeting Schedule
June 15, 2026
India Pre-Market Regulatory Roundup — June 15, 2026
India Pre-Market Regulatory Roundup
June 15, 2026
India Quarterly Results BSE NSE Announcements — June 15, 2026
India Quarterly Results BSE NSE Announcements